{
  "id": 2797908,
  "title": "ATAI Beckley earnings up next in final report before acquisition",
  "url": "https://urgent.news/2026/08/23/atai-beckley-earnings-up-next-in-final-report-before-acquisition",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-23T13:36:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/atai-beckley-earnings-up-next-in-final-report-before-acquisition-93CH-4872450"
  },
  "original_language": "en",
  "account": "ATAI Beckley Inc. unveiled its second-quarter earnings on Monday, signaling likely to be the final financial report before Eli Lilly's $2.8 billion acquisition. The deal, announced in July, entails up to $1 billion in contingent value rights contingent upon development milestones, with the transaction expected to close in the third quarter. Analysts anticipate a loss of $0.12 per share on $140,000 in revenue, representing a significant decline from first-quarter figures. Despite a modest 2.37% rise in EPS estimates over the past 60 days, they remain static over the past week. Among the 14 analysts covering ATAI, the consensus leans neutral, with an average price target of $8.10, suggesting a 9.8% potential upside from the present $7.42 share price. The stock trades above Lilly's $6.75 upfront offer, reflecting investor optimism over the milestone payments. As the merger progresses towards completion, the focus has shifted from ATAI's standalone performance to the deal's intricacies. The contingent value rights could potentially inject an additional $1 billion in value, contingent upon three milestones: the initiation of a Phase 3 trial for VLS-01 within four years, securing U.S. approval and DEA rescheduling for lead asset BPL-003 within five years, and achieving the same for VLS-01 within seven years. BPL-003, a DMT nasal spray for treatment-resistant depression, recently entered Phase 3, with pivotal data anticipated in early 2029. The company's cash reserves will be under the microscope to ensure a smooth closing without additional dilutive financing. Following the deal announcement, several analysts downgraded ATAI, citing merger arbitrage dynamics that curtail near-term upside. Oppenheimer, however, retained its Outperform rating, viewing the acquisition as validating their conviction in the transformative potential of psychedelic medicine. At present, Monday's earnings are primarily a reflection of the business Lilly is acquiring, rather than a catalyst for independent strategic decisions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}